Nantahala Capital Management, LLC
Position in EDIT — Editas Medicine, Inc.
CIK 1472322
New Canaan, CT
Position in EDIT
as of Jun 30, 2026
· filed Aug 19, 2026
Position Value
$2,762,748
New position
Shares Held
852,700
first reported quarter
Ownership
0.555%
of shares outstanding
% of Portfolio
0.17%
of 13F equity value
Holder Rank
#29
of 216 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Nantahala Capital Management, LLC holds $620,287,047 across 52 Biotechnology names. EDIT ranks #43 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SVRA |
Savara Inc
|
6,976,810 | $42,977,149 | |
| 2 | AVTX |
Avalo Therapeutics, Inc.
|
1,862,250 | $34,414,380 | |
| 3 | LBRX |
Lb Pharmaceuticals Inc
|
1,052,894 | $34,171,674 | |
| 4 | ABEO |
Abeona Therapeutics Inc.
|
5,136,490 | $31,743,508 | |
| 5 | ZVRA |
Zevra Therapeutics, Inc.
|
1,797,476 | $25,775,805 | |
| 6 | MLYS |
Mineralys Therapeutics, Inc.
|
820,481 | $22,136,577 | |
| 7 | QURE |
uniQure N.V.
|
455,660 | $20,987,699 | |
| 8 | AURA |
Aura Biosciences, Inc.
|
2,951,030 | $20,952,313 |
All Filings in EDIT
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,762,748 | 852,700 | Shares | Sole | 2026-08-19 | |
| No filing history on record for this holder in this stock. | ||||||